<DOC>
	<DOCNO>NCT00997919</DOCNO>
	<brief_summary>This Phase I , single-dose , randomize , parallel-group , open-label study evaluate safety , tolerability , pharmacokinetics MABT5102A follow subcutaneous ( SC ) intravenous ( IV ) administration healthy volunteer .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Pharmacokinetics , Bioavailability IV SC MABT5102A Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Male subject age 1850 year female subject age 1850 year childbearing potential good general health screen visit Body weight 50 100 kg For male subject reproductive potential , reliable mean contraception must use ( e.g. , abstinence condom ) duration study Exclusion Criteria Female subject reproductive potential . Subjects evidence clinically significant neurologic , psychiatric , hepatic , renal , hematologic , pulmonary , respiratory , immunologic system abnormality , acute infection , unstable medical disease Subjects malignancy ( exception completely excise basal cell squamous cell carcinoma skin ) History alcohol , drug , substance abuse within 6 month prior randomization , judgment investigator , may put subject risk unable participate fully study duration study Past history seizure , exception childhood febrile seizures Clinically significant laboratory ECG abnormalities Hospitalization 4 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>